A Phase 2 interventional study of vicadrostat / empagliflozin combination 1 and Spironolactone (drug) in CKD, Cardiovascular Diseases and Heart Failure, sponsored by University Medical Center Groningen. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by University Medical Center Groningen · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Heart Failure by University Medical Center Groningen — 8 open to participants now, 9 under way, 1 of them phase 3. Heart Failure · University Medical Center Groningen.
Among the 28 studies in Heart Failure by University Medical Center Groningen, this one is the 12th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2026, is one of 5 in phase 2, and was the 24th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →8 of the 28 studies in Heart Failure by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Women only · Healthy volunteers
University Medical Center Groningen · Sites in France, Germany, Italy and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2007; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 301 across the 18 interventional studies, 114 across the 10 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
1 of the studies in Heart Failure by University Medical Center Groningen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Heart Failure by University Medical Center Groningen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study, investigators will compare the effect of vicadrostat combined with empagliflozin with the effect of spironolactone combined with empagliflozin on renal function and changes in protein profiles in blood and urine.
The hypothesis is that the renal and cardiac responses between vicadrostat and spironolactone differ due to mechanistic differences in their mode of action. Spironolactone is a mineralocorticoid receptor antagonist (MRA) and exerts its effect on a receptor, or a type of "receiver," found on various cells. Vicadrostat is an aldosterone synthase inhibitor (ASI) and inhibits aldosterone production. Therefore, both drugs affect aldosterone.
However, studies evaluating the differences between MRAs (such as spironolactone) and ASI (such as vicadrostat) and examining their effects on the kidneys in patients with chronic kidney disease with concurrent cardiovascular disease, and/or heart failure are still lacking.
For this study, all participants will be divided into two groups:
The hypothesis is that renal and cardiac response to a mineralocorticoid receptor antagonist (MRA) differs from the response to an aldosterone synthase inhibitor (ASi) due to the mechanistic differences in action between these two compounds. However, direct head-to-head comparative studies evaluating the renal, cardiac, and systemic effects of MRAs and ASi in patients with chronic kidney disease (CKD), with concomitant cardiovascular disease (CVD) or heart failure (HF), are lacking.
The main objective of this study in patients with chronic kidney disease with either cardiovascular disease and/or or heart failure is to compare the effects of the ASi, vicadrostat, with the steroidal MRA, spironolactone, on the change in kidney function from baseline to 4 and 26 weeks.
Secondary objectives include
This is a mechanistic trial using an open-label, parallel-group comparative design with 1:1 randomization and blinded endpoint assessment.
Treatment with vicadrostat (Investigational Medicinal Product; IMP 10mg daily) or spironolactone (Comparator IMP; 25-50mg daily) for 26 weeks whilst on empagliflozin (Auxiliary Medicinal Product; AxMP 10mg daily). In half of the enrolled subjects (targeted 50 subjects) renal hemodynamic measurements will be performed at baseline, at 4 and at 26 weeks.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
This study's planned enrollment of 100 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with
Outpatient.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
daily treatment with Vicadrostat and background Empagliflozin
Drug: vicadrostat / empagliflozin combination 1
daily treatment with Spironlactone and background Empagliflozin
Drug: Spironolactone (drug)
Group 1
Group 2
Kidney function (eGFR)
Changes in kidney function as determined by change in eGFR
Time frame: From baseline to 4 and 26 weeks of treatment.
Renal hemodynamic measurements
Changes in renal hemodynamic measurements
Time frame: From baseline to 4 and 26 weeks of treatment
Plasma protein profiles
Plasma protein profiles via proteomics
Time frame: From baseline to 4 and 26 weeks of treatment
Urinary protein profiles
Urinary protein profiles via proteomics
Time frame: From baseline to 4 and 26 weeks of treatment
Changes in blood concentration markers
Changes in blood (serum and plasma) concentrations of potassium, creatinine, neutrophil gelatinase-associated lipocalin (NGAL), renin, angiotensin II, aldosterone, and kidney injury molecule-1 (KIM-1).
Time frame: From baseline to 4 and 26 weeks of treatment
Changes in urinary concentration markers
Changes in urinary concentration of sodium, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1)
Time frame: From baseline to 4 and 26 weeks of treatment
Changes in UACR
Changes in UACR
Time frame: From baseline to 4 and 26 weeks.
Plan to share: Undecided — will be updated at a later stage
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Feb 2028, 21 months after the start.
Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 21 months is below that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen →